A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis

Journal:

Arthritis & Rheumatology

Published:

2025-08-29

DOI:

10.1002/art.43366

Affiliations:

17

Authors:

34

Go to article

Institutions	Authors	Share
University of Colorado Anschutz Medical Campus (CU Anschutz), United States of America (USA)	9.000000	0.26
Rho, United States of America (USA)	5.000000	0.15
Oklahoma Medical Research Foundation (OMRF), United States of America (USA)	3.000000	0.09
University of Nebraska Medical Center (UNMC), United States of America (USA)	2.000000	0.06
UCLA Health, United States of America (USA)	2.000000	0.06
NIH National Institute of Allergy and Infectious Diseases (NIAID), United States of America (USA)	2.000000	0.06
Brigham and Women's Hospital (BWH), United States of America (USA)	1.000000	0.03
Mayo Clinic, United States of America (USA)	1.000000	0.03
University of California, San Francisco (UCSF), United States of America (USA)	1.000000	0.03
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA)	1.000000	0.03
Cedars-Sinai Medical Center (Cedars-Sinai), United States of America (USA)	1.000000	0.03
Emory University, United States of America (USA)	1.000000	0.03
Augusta University, United States of America (USA)	1.000000	0.03
The University of Alabama at Birmingham (UAB), United States of America (USA)	1.000000	0.03
Feinstein Institutes for Medical Research, Northwell Health, United States of America (USA)	1.000000	0.03
University of Massachusetts Chan Medical School (UMass Chan Medical School), United States of America (USA)	1.000000	0.03
Michigan Medicine, U-M, United States of America (USA)	1.000000	0.03

Interested in Pharmacology and Pharmaceutical Sciences?